Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05956821 · ClinicalTrials.gov registry record · Phase 1
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
A Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05956821: Recruiting Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma, sponsored by University of Miami.
NCT05956821 is a Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 20 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05956821, a Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.
Primary Outcome
The number of treatment-related adverse events will be assessed and graded according to the NCI Common Toxicity Criteria, version 5.0.
Conditions Studied
Interventions
- DRUG SIACI of cetuximab and bevacizumab
Study Locations (1)
Florida
- Jackson Memorial Hospital - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-19 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 1 |
What NCT05956821 shows while recruiting
NCT05956821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (79% lower).
The record links to 8 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which SIACI of cetuximab and bevacizumab is the first listed.
NCT05956821 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05956821 about?
NCT05956821 is a clinical study titled "Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age". This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.
What is the current status of trial NCT05956821?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-06-19. Estimated completion is 2029-12-01.
What conditions does trial NCT05956821 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Diffuse Intrinsic Pontine Glioma, Oligodendroglioma, H3 K27M.
What interventions are being tested in trial NCT05956821?
The interventions under investigation include: SIACI of cetuximab and bevacizumab (DRUG).
Who is sponsoring clinical trial NCT05956821?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05956821 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05956821's enrollment target sits among peer trials
20 70th of 88 higher than 19 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
-
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI